WEALTH ENHANCEMENT ADVISORY SERVICES, LLC

Position in ALNY — Alnylam Pharmaceuticals, Inc.

CIK 1632972 PLYMOUTH, MN

Position in ALNY

as of Jun 30, 2026 · filed Jul 15, 2026 Compact

Position Value

$2,255,918

-$549,197 QoQ

Shares Held

7,494

-11.6% QoQ

Ownership

0.006%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

of 56 holders

Holding Since

Jun 2020

13 quarters on record

Voting authority Sole 1.9749132639444889.ToString("F0")% Shared 0.ToString("F0")% None 98.02508673605551.ToString("F0")%

Healthcare · as of Jun 30, 2026

WEALTH ENHANCEMENT ADVISORY SERVICES, LLC holds $166,117,226 across 147 Biotechnology names. ALNY ranks #12 (1.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	45,889	$22,794,442
2	REGN	Regeneron Pharmaceuticals, Inc.	33,880	$21,125,535
3	INCY	Incyte Corp	151,505	$17,174,606
4	EXEL	Exelixis, Inc.	207,728	$11,302,480
5	RPRX	Royalty Pharma plc	179,888	$10,086,320
6	CORT	Corcept Therapeutics Inc	76,278	$6,632,372
7	HALO	Halozyme Therapeutics, Inc.	70,797	$5,541,281
8	AXSM	Axsome Therapeutics, Inc.	19,919	$4,875,573

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,255,918	7,494	-11.6%	Shares	Sole	2026-07-15
2026-03-31	$2,805,115	8,478	-39.8%	Shares	Sole	2026-04-08
2025-12-31	$5,601,695	14,087	-3.0%	Shares	Sole	2026-01-08
2025-09-30	$6,623,400	14,525	+183.8%	Shares	Sole	2025-10-29
2025-06-30	$1,668,928	5,118	-64.5%	Shares	Sole	2025-07-10
2025-03-31	$3,889,368	14,404	+14.6%	Shares	Sole	2025-04-16
2024-12-31	$2,956,905	12,566	+94.7%	Shares	Sole	2025-03-17
2024-09-30	$1,775,043	6,454	+56.2%	Shares	Sole	2024-10-24
2024-06-30	$1,003,833	4,131	+40.2%	Shares	Sole	2024-07-16
2024-03-31	$440,429	2,947	+22.8%	Shares	Sole	2024-04-15
2023-12-31	$459,192	2,399	+9.9%	Shares	Sole	2024-01-30
2023-09-30	$386,609	2,183	-75.1%	Shares	Sole	2023-11-13
2020-06-30	$1,297,147	8,758	—	Shares	Sole	2020-10-13
No filing history on record for this holder in this stock.